A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin Paclitaxel Plus Concurrent and Extended Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated, Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Roche
- 08 Nov 2019 Planned End Date changed from 10 Mar 2021 to 10 Apr 2021.
- 19 Sep 2019 Planned End Date changed from 3 Feb 2021 to 10 Mar 2021.
- 24 Aug 2018 New trial record